Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

BioNTech SE ADR buy Sargnagel

Start price
€289.50
08.09.21 / 60%
Target price
€333.00
08.09.22
Performance (%)
-49.48%
End price
€146.25
09.09.22
Summary
This prediction ended on 09.09.22 with a price of €146.25. Massive losses of -49.48% were the result for the BUY prediction by Sargnagel. Sargnagel has 60% into this prediction This prediction was marked as speculative and is excluded from Sargnagel's performance statistics.
Performance without dividends (%)
Name 1w 1m 1y
BioNTech SE ADR 7.896% 7.896% 243.124%
iShares Core DAX® 2.149% 5.415% 21.385%
iShares Nasdaq 100 0.838% 1.926% 44.386%
iShares Nikkei 225® 1.143% 2.887% 27.641%
iShares S&P 500 1.265% 3.698% 33.327%

According to Sargnagel what are the pros and cons of BioNTech SE ADR for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Capable Management
Growths faster than the competition
Innovative
Known brand
Top 10 in its market
Standard Investments for future growth
Fair valuation
EBIT growth >5% per year expected
Revenue growth >5% per year expected
Some uniques
Cons
Higher risks for its business

Comments by Sargnagel for this prediction

In the thread Biontech SE diskutieren
Prediction Buy
Perf. (%) -49.48%
Target price
Change
Ends at 08.09.22

Buy BioNTech SE ADR

Prediction Buy
Perf. (%) -49.48%
Target price 333.000
Change
Ends at 08.09.22

Kursziel gesetzt auf 333,0

In the thread Trading Biontech SE
Prediction Sell
Perf. (%) -49.48%
Target price 333.000
Change
Ends at 08.09.22

Die von Sargnagel gewählte maximale Laufzeit wurde überschritten

Stopped prediction by Sargnagel for BioNTech SE ADR

BioNTech SE ADR

Start price
Target price
Perf. (%)
€337.70
05.08.21
-
05.08.22
-14.27%
08.09.21

Could be worthwhile Investment >10% per year
Capable Management
Growths faster than the competition
Higher risks for its business